Abstract: Tafluprost is a prostaglandin analogue (PGA) with strong FP receptor affinity, which was first reported in 2003. Whereafter, Tafluprost eye drops, as the first originally developed preservative-free PGA agent, came on the market, and has been used as the first-line drug in the treatment of open-angle glaucoma and ocular hypertension. The unique difluoride atomic structure gives tafluprost stronger metabolic stability, making it perform similar efficacy with a lower concentration compared to other PGA. A large number of clinical studies on tafluprost eye drops have confirmed its effect of reducing intraocular pressure, and the adverse reactions occur less and to a lesser degree. In addition to reducing intraocular pressure, tafluprost is considered to have other pharmacological effects, including ocular blood flow improvement and optic nerve protection, as well as a protective effect on other ocular tissues. Recent clinical trials have begun to focus more on the evaluation of the safety of preservative-free tafluprost eye drops, especially for the ocular surface condition. In 2022, the preservative-free tafluprost eye drops (Tapros) were marketed in China. This article will review the pharmacological mechanism and pharmacokinetics of tafluprost, and discuss its clinical efficacy, safety, and tolerability of preservative-free tafluprost eye drops to provide clinical guidance. (Int Rev Ophthalmol, 2023, 47: 193-202)

Key words: tafluprost eye drops, glaucoma